China National Pharmaceutical Group plans to uniformly register and issue RMB 30 billion non-financial corporate debt financing instruments within China

According to the news from Zhitong Finance and Economics APP, China National Pharmaceutical Group Corporation (01099) announced that, in order to meet the actual needs of supplementing operating and reserve funds, ensuring smooth direct financing channels, reducing financing costs, and improving debt structure, on April 26, 2024, the board of directors proposed to register and issue a quota of Non-Financial Corporate Debt Financing Instruments (TDFI) within China.

The registered amount is a quota of RMB 30 billion for non-financial corporate debt financing instruments, including: RMB 25 billion for short-term varieties (within one year) and RMB 5 billion for medium to long-term varieties (generally not exceeding 10 years). The raised funds will be used for purposes including but not limited to repaying financial institution loans, credit-related matured bonds, supplementing operating and reserve funds, as well as other purposes in compliance with relevant laws and regulations. The funds raised from medium to long-term varieties can also be used for project construction